Clinical trial · Observational
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
A Registry to Collect Characteristics and Outcomes From Patients With Solid Tumors Profiled With a Next-Generation Sequencing Test (WAYFIND-R)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumours | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- From date of registry entry until death, for up to 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant is an adult (according to the age of majority as defined by local regulations) * Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date) * Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results * Informed consent has been obtained from the participant or legally authorized representative, as per local regulations Exclusion Criteria: -Participant has a prior or current diagnosis of haematological malignancy
References
Publications (1)
- DERIVEDDienstmann R, Hackshaw A, Blay JY, Le Tourneau C. Core variables for real-world clinicogenomic data collection in precision oncology. ESMO Real World Data Digit Oncol. 2025 Feb 27;7:100117. doi: 10.1016/j.esmorw.2025.100117. eCollection 2025 Mar. PMID 41647341